Imeglimin CAS 775351-65-0

Product Description:

Product Name: imeglimin CAS NO: 775351-65-0

Synonyms:

Imeglimin;

UNII-UU226QGU97;

Chemical & Physical Properties:

Appearance: Solid powder

Assay: ≥98.0%

Density: 1.29±0.1 g/cm3 (Predicted)

Boiling Point: 239.9±23.0℃(Predicted)

Solubility: Soluble in DMSO

Imeglimin is the first in a new tetrahydrotriazine-containing class of oral antidiabetic agents, the glimins. It has been shown to act on the liver, muscle and pancreatic β-cells to uniquely target the key defects of type 2 diabetes. Imeglimin is an experimental drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.

Imeglimin is in development (completed phase IIb clinical trials) for use both as monotherapy and in combination with other type-2 diabetes treatments.

Various research protocols are being known through various scientists. Early studies showed that imeglimin is as effective as metformin in regulating glycaemic control.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.